Aptose Biosciences (APTO) 6-K 7 Aug 18 2018 Q2 Condensed Consolidated Interim Statements of Financial Position Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	Aptose Biosciences Inc.
Entity Central Index Key	882,361
Trading Symbol	apto
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Type	6-K
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Interim

Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents (note 4(a))	$ 17,944	$ 10,631
Investments (note 4(b))	520	798
Prepaid expenses and other assets	593	396
Total current assets	19,057	11,825
Non-current assets
Property and equipment	231	142
Total non-current assets	231	142
Total assets	19,288	11,967
Current liabilities
Accounts payable and accrued liabilities	2,401	1,765
Total current liabilities	2,401	1,765
Shareholders’ equity:
Common shares (note 6)	253,081	231,923
Stock options (note 7)	9,065	6,456
Contributed surplus	22,909	22,909
Accumulated other comprehensive loss	(4,298)	(4,298)
Deficit	(263,870)	(246,788)
Total shareholders’ equity	16,887	10,202
Total liabilities and shareholders’ equity	$ 19,288	$ 11,967

Condensed Consolidated Interim3

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Revenue
Expenses:
Research and development (note 9)	7,818	1,088	10,958	2,823
General and administrative (note 9)	2,511	1,393	6,213	2,983
Operating Expenses	10,329	2,481	17,171	5,806
Finance expense (note 9)	11		29
Finance income (note 9)	(74)	(40)	(118)	(73)
Net finance income	(63)	(40)	(89)	(73)
Net loss and comprehensive loss for the period	$ (10,266)	$ (2,441)	$ (17,082)	$ (5,733)
Basic and diluted loss per common share (in dollars per share)	$ (0.30)	$ (0.11)	$ (0.56)	$ (0.30)
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (000’s) note 6(b)) (in shares)	33,950	21,309	30,744	19,375

Condensed Consolidated Interim4

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Issued capital [member]	Reserve of share-based payments [member]	Share premium [member]	Accumulated other comprehensive income [member]	Retained earnings [member]	Total
Balance (in shares) at Dec. 31, 2016	15,722
Balance at Dec. 31, 2016	$ 218,034	$ 7,306	$ 21,413	$ (4,298)	$ (235,127)	$ 7,328
Statement Line Items [Line Items]
Common shares issued (in shares)	7,473
Common shares issued	$ 8,204					8,204
Stock-based compensation (note 7)		510				510
Net loss for the period					(5,733)	(5,733)
Common shares issued on redemption of restricted share units (note 7) (in shares)	150
Common shares issued on redemption of restricted share units (note 7)	$ 171	(171)
Expiry of vested stock options		(1,287)	1,287
Balance (in shares) at Jun. 30, 2017	23,345
Balance at Jun. 30, 2017	$ 226,409	6,358	22,700	(4,298)	(240,860)	10,309
Balance (in shares) at Dec. 31, 2017	27,502
Balance at Dec. 31, 2017	$ 231,923	6,456	22,909	(4,298)	(246,788)	10,202
Statement Line Items [Line Items]
Common shares issued (in shares)	1,430
Common shares issued	$ 5,246					5,246
Common shares issued pursuant to share purchase agreement (note 6(a)(ii)) (in shares)	5,232
Common shares issued pursuant to share purchase agreement (note 6(a)(ii))	$ 14,995					14,995
Common shares issued pursuant to 2018 share purchase agreement (note 6(a)(iii)) (in shares)	170
Common shares issued pursuant to 2018 share purchase agreement (note 6(a)(iii))	$ 600					600
Common shares issued upon exercise of stock options (note 7) (in shares)	77
Common shares issued upon exercise of stock options (note 7)	$ 317	(134)				183
Stock-based compensation (note 7)		2,743				2,743
Net loss for the period					(17,082)	(17,082)
Balance (in shares) at Jun. 30, 2018	34,411
Balance at Jun. 30, 2018	$ 253,081	$ 9,065	$ 22,909	$ (4,298)	$ (263,870)	$ 16,887

Condensed Consolidated Interim5

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss for the period	$ (10,266)	$ (2,441)	$ (17,082)	$ (5,733)
Items not involving cash:
Stock-based compensation	515	449	2,743	510
Shares issued to Aspire Capital as commitment fees (note 6(a)(iii))	600		600
Depreciation and amortization	19	23	35	46
Interest income	(74)	(11)	(118)	(19)
Unrealized foreign exchange (loss) gain		(29)	28	(50)
Change in non-cash operating working capital (note 8)	(51)	(631)	439	(47)
Cash used in operating activities	(9,257)	(2,640)	(13,355)	(5,293)
Cash flows from financing activities:
Issuance of common shares under the 2018 ATM, net of issuance costs (note 6(a)(i))	5,246		5,246
Issuance of common shares under Share Purchase Agreement (note 6(a)(ii))	6,140		14,995
Issuance of common shares under the ATM, net of issuance costs (note 6(a)(iv))		4,528		8,204
Issuance of common shares upon exercise of stock options (note 7)	183		183
Cash provided by financing activities	11,569	4,528	20,424	8,204
Cash flows from (used in) investing activities:
Maturity (acquisition) of investments	250	(2,985)	250	(2,985)
Purchase of property and equipment	(100)		(124)
Interest received	74	11	118	19
Cash provided by (used in) investing activities	224	(2,974)	244	(2,966)
Effect of exchange rate fluctuations on cash and cash equivalents held		29		50
Increase (decrease) in cash and cash equivalents	2,536	(1,057)	7,313	(5)
Cash and cash equivalents, beginning of year	15,408	8,992	10,631	7,940
Cash and cash equivalents, end of year	$ 17,944	$ 7,935	$ 17,944	$ 7,935

Note 1 - Reporting Entity

Note 1 - Reporting Entity	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of notes and other explanatory information [text block]	1. Reporting Entity Aptose Biosciences Inc. ("Aptose" or the "Company") is a clinical-stage biotechnology company committed to developing highly differentiated therapeutics that target the underlying mechanisms and unmet medical needs in oncology. Aptose is a publicly listed company incorporated under the laws of Canada. The Company's shares are listed on the Nasdaq Capital Markets and the Toronto Stock Exchange. The head office, principal address and records of the Company are located at 251 1105, M2J 4R3.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of basis of preparation of financial statements [text block]	2. Basis of presentation (a) Statement of Compliance These unaudited condensed consolidated interim financial statements of the Company as at June 30, 2018, 34, Interim Financial Reporting not not three six June 30, 2018, not may December 31, 2018. December 31, 2017. The unaudited condensed consolidated interim financial statements of the Company were reviewed by the Audit Committee and approved and authorized for issue by the Board of Directors on August 7, 2018. (b) Functional and presentation currency The functional and presentation currency of the Company is the US dollar. (c) Significant accounting judgments, estimates and assumptions The preparation of these unaudited condensed consolidated interim financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the unaudited condensed consolidated interim financial statements and reported amounts of revenues and expenses during the reporting period. Actual outcomes could differ from these estimates. Management’s assessment of the Company’s ability to continue as a going concern involves making a judgment, at a particular point in time, about inherently uncertain future outcomes and events or conditions. Please see note 5 The unaudited condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the unaudited condensed consolidated interim financial statements, and may

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of significant accounting policies [text block]	3. Significant accounting policies The accompanying unaudited condensed consolidated interim financial statements follow the same accounting policies and methods of application as the audited consolidated financial statements of the Company for the year ended December 31, 2017, a) Policies adopted in the period IFRS 9, Financial Instruments 9" IFRS 9 2014 9 2014 9 2014 not not b) Recent accounting pronouncements not IFRS 16, Leases 16” On January 13, 2016, 16 Leases January 1, 2019. 16 17 12 not

Note 4 - Capital Disclosures

Note 4 - Capital Disclosures	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of capital [text block]	4. Capital disclosures Our primary objective when managing capital is to ensure that we have sufficient cash resources to fund our development activities and to maintain our ongoing operations. To secure the additional capital necessary to pursue these plans, we may We include cash and cash equivalents and short-term investments in the definition of capital. We are not no three six June 30, 2018. In March 2018, “2018 $100,000,000 may one may 2018 may second “2018 Under the terms of the ATM facility with Cantor Fitzgerald, we may, $30 2018 $20.0 30 (a) Cash and cash equivalents: Cash and cash equivalents consists of cash of $1.053 December 31, 2017 - $3.225 three $16.891 December 31, 2017 - $7.406 (b) Investments: As at June 30, 2018 December 31, 2017, October 10, 2018, 1.45% .

Note 5 - Financial Instruments

Note 5 - Financial Instruments	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of financial instruments [text block]	5. Financial instruments (a) Financial instruments The Company financial instruments are as follows: As at June 30, 2018 As at December 31, 2017 Financial assets Cash and cash equivalents (consisting of high interest savings accounts, treasury bill and short-term bankers’ acceptance), measured at amortized cost $ 17,944 $ 10,631 Investments, consisting of fixed income securities, measured at amortized cost 520 798 Financial liabilities Accounts payable and accrued liabilities, measured at amortized cost $ 2,401 $ 1,765 At June 30, 2018, no (b) Financial risk management The Company has exposure to credit risk, liquidity risk, foreign currency risk and market risk. The Company's Board of Directors has the overall responsibility for the oversight of these risks and reviews the Company's policies on an ongoing basis to ensure that these risks are appropriately managed. (i) Credit risk Credit risk is the risk of financial loss to the Company if a customer, partner or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's cash and cash equivalents. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk for its cash and cash equivalents and short-term investments by maintaining minimum standards of R1 (ii) Liquidity risk Liquidity risk is the risk that the Company will not not In managing its liquidity risk, the Company has considered its available cash and cash equivalents and short-term investments as at June 30, 2018. 2018 twelve June 30, 2019. After considering the above factors, management has concluded that there are no may may (iii) Foreign currency risk Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. We are exposed to currency risk from employee costs as well as the purchase of goods and services for activities in Canada and the cash balances held in foreign currencies. Fluctuations in the Canadian dollar exchange rate could potentially have a significant impact on the Company’s results. Assuming all other variables remain constant, a 10% $44 June 30, 2018, CA$ Balances at CA$ Balances at Cash and cash equivalents $ 303 $ 83 Investments 706 1,000 Accounts payable and accrued liabilities (429 ) (384 ) Balance, end of period $ 580 $ 699 The Company does not (iv) Market risk Market risk is the risk that changes in market prices, such as interest rates, foreign exchange rates and equity prices will affect the Company's income or the value of its financial instruments. The Company is subject to interest rate risk on its cash and cash equivalents and investments. The Company does not not

Note 6 - Share Capital

Note 6 - Share Capital	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of share capital, reserves and other equity interest [text block]	6. Share capital The Company is authorized to issue an unlimited number of common shares. (a) Equity issuances: i) 2018 On March 28, 2018, may, $30 During the three six June 30, 2018, 1,429,847 $3.78 $5.41 $ 5.25 3% ii) 2017 On October 27, 2017, $15,500,000 30 October 31, 2017, 357,143 $500 $324 321,429 June 30, 2018, $15.5 During the six June 30, 2018, 5,231,953 $2.87 $15 iii) 2018 On May 30, 2018, 2018 $20 30 June 8, 2018, 170,261 2018 $600 June 30, 2018, not 2018 iv) 2015 On April 2, 2015, $20 December 29, 2017 $20 During the three June 30, 2017, 7,472,618 $1.14 $8.5 $8.2 3% (b) Loss per share Loss per common share is calculated using the weighted average number of common shares outstanding for the three six June 30, 2018 2017 Three months ended Six months ended 2018 2017 2018 2017 Issued common shares, beginning of period 32,225 18,944 27,502 15,722 Effect of ATM issuances 459 2,362 231 3,651 Effect of shares issued pursuant to share purchase agreements 1,257 - 3,007 - Effect of exercise of stock options 9 - 4 - Effect of RSUs redemptions - 3 - 2 33,950 21,309 30,744 19,375 The effect of any potential exercise of our stock options outstanding during the period has been excluded from the calculation of diluted loss per common share as it would be anti-dilutive.

Note 7 - Other Equity

Note 7 - Other Equity	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of share-based payment arrangements [text block]	7. Other equity (a) Stock options transactions for the period: Six months ended Six months ended Number of Weighted average Number of Weighted Outstanding, Beginning of period 2,344 $ 3.46 2,005 $ 4.31 Granted 2,084 2.96 728 1.10 Exercised (77 ) 2.31 - - Forfeited (17 ) 2.01 (142 ) 3.65 Expired - - (263 ) 4.97 Outstanding, end of period 4,334 $ 3.16 2,328 3.40 (b) Stock options outstanding at June 30, 2018: Options outstanding Options exercisable Range of exercise prices Options Weighted Weighted Options Weighted $1.03-$2.66 824 8.5 $ 1.26 401 $ 1.28 $2.67-$2.85 790 9.6 2.78 790 2.78 $2.86-$3.00 359 7.9 2.91 184 2.91 $3.01-$3.97 1,165 9.5 3.09 28 3.70 $3.98-$32.88 1,196 6.1 4.87 1,158 4.86 4,334 8.2 $ 3.16 2,561 $ 3.51 (c) Fair value assumptions The following table presents the weighted average assumptions that were used in the Black-Scholes option pricing model to determine the fair value of stock options granted during the period, and the resultant weighted average fair values: Six months ended June 30, 2018 Six months ended June 30, 2017 Weighted average risk-free interest rate 2.39 % 1.24 % Expected dividend yield — — Weighted average expected volatility 93.9 % 100.2 % Weighted average expected life of options (in years) 5 5 Weighted average grant date fair value $ 2.14 $ 0.81 The Company uses historical data to estimate the expected dividend yield and expected volatility of its common shares in determining the fair value of stock options. The expected life of the options represents the estimated length of time the options are expected to remain outstanding. Stock options granted by the Company during the six June 30, 2018 50% one 16.67% three 116,000 50% one 25% two 850,000 three six June 30, 2018, $515 2017 $286 $2.743 2017 $339 Refer to note 9 The Company has available up to 6,021,923 June 30, 2018. (d) Restricted share units The Company has a stock incentive plan (SIP) pursuant to which the Board may one six June 30, 2018, Six months ended, Six months ended, Number Weighted Number Weighted Outstanding, beginning of period - $ - - $ - Granted - - 150 1.14 Redeemed - - (150 ) 1.14 Outstanding, end of period - $ - - $ - On March 28, 2017 150,000 three three six June 30, 2018, $nil 2017 $163 $nil 2017 $171 The grant date fair value was determined as the closing value of the common shares of the Company on the Toronto Stock Exchange on the date prior to the date of grant.

Note 8 - Additional Cash Flow D

Note 8 - Additional Cash Flow Disclosures	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of cash flow statement [text block]	8. Additional cash flow disclosures Net change in non-cash operating working capital is summarized as follows: Three months ended Six months ended 2018 2017 2018 2017 Prepaid expenses and other assets $ (247 ) $ 119 $ (197 ) $ 262 Accrued payables and accrued liabilities 196 (750 ) 636 (309 ) Net (used) provided $ (51 ) $ (631 ) $ 439 $ (47 )

Note 9 - Other Expenses

Note 9 - Other Expenses	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Components of other expenses [text block]	9. Other expenses Components of research and development expenses: Three months ended Six months ended 2018 2017 2018 2017 Program costs, excluding salaries $ 2,201 $ 692 $ 4,476 $ 1,939 Salaries 457 314 946 743 License fee, CrystalGenomics (note 9(a),(b)) 5,000 - 5,000 - Stock-based compensation 152 73 519 123 Depreciation and amortization 8 9 17 18 $ 7,818 $ 1,088 $ 10,958 $ 2,823 a) On May 7, 2018, $2.0 806 10. b) On June 13, 2018, $3.0 806 10. Components of general and administrative expenses: Three months ended Six months ended 2018 2017 2018 2017 General and administrative excluding salaries $ 1,003 $ 560 $ 2,296 $ 1,268 Salaries 533 443 1,074 1,301 Stock-based payment financing fees (note 6(a)(iii) 600 - 600 - Stock-based compensation 364 376 2,225 386 Depreciation and amortization 11 14 18 28 $ 2,511 $ 1,393 $ 6,213 $ 2,983 Components of finance expense: Three months ended Six months ended 2018 2017 2018 2017 Foreign exchange loss $ 11 $ - $ 28 $ - Components of finance income: Three months ended Six months ended 2018 2017 2018 2017 Interest income $ 74 $ 11 $ 118 $ 19 Foreign exchange gain - 29 - 54 $ 74 $ 40 $ 118 $ 73

Note 10 - Commitments, Continge

Note 10 - Commitments, Contingencies and Guarantees	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of other provisions, contingent liabilities and contingent assets [text block]	10. Commitments, contingencies and guarantees Less than 1 – 3 years 3 – 5 years Greater than Total Operating leases $ 280 $ 505 $ 518 $ 213 $ 1,516 The Company has entered into various contracts with service providers with respect to the clinical development of APTO- 253 CG’806. $3.2 The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may Under the license agreement with CrystalGenomics, the Company has obligations for development milestones of $16 2 $44 may not On June 13, 2018, 806 $6 2 $20 may not

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of related party [text block]	11. Related Party Transactions The Company uses Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company. Dr. Stephen Howell is the Acting Chief Medical Officer of Aptose and is also a Professor of Medicine at UCSD and oversees the laboratory work. The work is completed under the terms of research services agreements executed in March 2015 March 2018, twelve $300,000. During the six June 30, 2018, $143 2017 $122

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Discloure of Significant Accounting Policies
Description of accounting policy for new accounting pronouncements [text block]	a) Policies adopted in the period IFRS 9, Financial Instruments 9" IFRS 9 2014 9 2014 9 2014 not not b) Recent accounting pronouncements not IFRS 16, Leases 16” On January 13, 2016, 16 Leases January 1, 2019. 16 17 12 not

Note 5 - Financial Instruments

Note 5 - Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of detailed information about financial instruments [text block]	As at June 30, 2018 As at December 31, 2017 Financial assets Cash and cash equivalents (consisting of high interest savings accounts, treasury bill and short-term bankers’ acceptance), measured at amortized cost $ 17,944 $ 10,631 Investments, consisting of fixed income securities, measured at amortized cost 520 798 Financial liabilities Accounts payable and accrued liabilities, measured at amortized cost $ 2,401 $ 1,765
Disclosure of currency risk [text block]	CA$ Balances at CA$ Balances at Cash and cash equivalents $ 303 $ 83 Investments 706 1,000 Accounts payable and accrued liabilities (429 ) (384 ) Balance, end of period $ 580 $ 699

Note 6 - Share Capital (Tables)

Note 6 - Share Capital (Tables)	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of earnings per share [text block]	Three months ended Six months ended 2018 2017 2018 2017 Issued common shares, beginning of period 32,225 18,944 27,502 15,722 Effect of ATM issuances 459 2,362 231 3,651 Effect of shares issued pursuant to share purchase agreements 1,257 - 3,007 - Effect of exercise of stock options 9 - 4 - Effect of RSUs redemptions - 3 - 2 33,950 21,309 30,744 19,375

Note 7 - Other Equity (Tables)

Note 7 - Other Equity (Tables)	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of number and weighted average exercise prices of share options [text block]	Six months ended Six months ended Number of Weighted average Number of Weighted Outstanding, Beginning of period 2,344 $ 3.46 2,005 $ 4.31 Granted 2,084 2.96 728 1.10 Exercised (77 ) 2.31 - - Forfeited (17 ) 2.01 (142 ) 3.65 Expired - - (263 ) 4.97 Outstanding, end of period 4,334 $ 3.16 2,328 3.40
Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]	Options outstanding Options exercisable Range of exercise prices Options Weighted Weighted Options Weighted $1.03-$2.66 824 8.5 $ 1.26 401 $ 1.28 $2.67-$2.85 790 9.6 2.78 790 2.78 $2.86-$3.00 359 7.9 2.91 184 2.91 $3.01-$3.97 1,165 9.5 3.09 28 3.70 $3.98-$32.88 1,196 6.1 4.87 1,158 4.86 4,334 8.2 $ 3.16 2,561 $ 3.51
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]	Six months ended June 30, 2018 Six months ended June 30, 2017 Weighted average risk-free interest rate 2.39 % 1.24 % Expected dividend yield — — Weighted average expected volatility 93.9 % 100.2 % Weighted average expected life of options (in years) 5 5 Weighted average grant date fair value $ 2.14 $ 0.81
Disclosure of number and weighted average exercise prices of other equity instruments [text block]	Six months ended, Six months ended, Number Weighted Number Weighted Outstanding, beginning of period - $ - - $ - Granted - - 150 1.14 Redeemed - - (150 ) 1.14 Outstanding, end of period - $ - - $ -

Note 8 - Additional Cash Flow21

Note 8 - Additional Cash Flow Disclosures (Tables)	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Net change in non-cash operating working capital [text block]	Three months ended Six months ended 2018 2017 2018 2017 Prepaid expenses and other assets $ (247 ) $ 119 $ (197 ) $ 262 Accrued payables and accrued liabilities 196 (750 ) 636 (309 ) Net (used) provided $ (51 ) $ (631 ) $ 439 $ (47 )

Note 9 - Other Expenses (Tables

Note 9 - Other Expenses (Tables)	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of components of research and development expense [text block]	Three months ended Six months ended 2018 2017 2018 2017 Program costs, excluding salaries $ 2,201 $ 692 $ 4,476 $ 1,939 Salaries 457 314 946 743 License fee, CrystalGenomics (note 9(a),(b)) 5,000 - 5,000 - Stock-based compensation 152 73 519 123 Depreciation and amortization 8 9 17 18 $ 7,818 $ 1,088 $ 10,958 $ 2,823
Disclosure of components of general and administrative expense [text block]	Three months ended Six months ended 2018 2017 2018 2017 General and administrative excluding salaries $ 1,003 $ 560 $ 2,296 $ 1,268 Salaries 533 443 1,074 1,301 Stock-based payment financing fees (note 6(a)(iii) 600 - 600 - Stock-based compensation 364 376 2,225 386 Depreciation and amortization 11 14 18 28 $ 2,511 $ 1,393 $ 6,213 $ 2,983
Disclosure of finance income (cost) [text block]	Three months ended Six months ended 2018 2017 2018 2017 Foreign exchange loss $ 11 $ - $ 28 $ - Three months ended Six months ended 2018 2017 2018 2017 Interest income $ 74 $ 11 $ 118 $ 19 Foreign exchange gain - 29 - 54 $ 74 $ 40 $ 118 $ 73

Note 10 - Commitments, Contin23

Note 10 - Commitments, Contingencies and Guarantees (Tables)	6 Months Ended
	Jun. 30, 2018
Statement Line Items [Line Items]
Disclosure of finance lease and operating lease by lessee [text block]	Less than 1 – 3 years 3 – 5 years Greater than Total Operating leases $ 280 $ 505 $ 518 $ 213 $ 1,516

Note 4 - Capital Disclosures (D

Note 4 - Capital Disclosures (Details Textual) - USD ($)	Jun. 30, 2018	May 30, 2018	Mar. 31, 2018	Mar. 28, 2018	Dec. 31, 2017
Statement Line Items [Line Items]
Maximum equity authorised			$ 100,000,000
Total cash	$ 1,053,000				$ 3,225,000
Total cash equivalents	$ 16,891,000				$ 7,406,000
Investments, Interest Rate	1.45%				1.45%
Aspire purchase agreement 2018 [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value		$ 20,000,000
Cantor Fitzgerald [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value				$ 30,000,000

Note 5 - Financial Instrument25

Note 5 - Financial Instruments (Details Textual) $ in Thousands	Jun. 30, 2018USD ($)
Statement Line Items [Line Items]
Value at risk	$ 0
Floating interest rate [member]
Statement Line Items [Line Items]
Total financial liabilities	0
Forward contract [member]
Statement Line Items [Line Items]
Financial instruments designated as hedging instruments, at fair value	0
Currency risk [member]
Statement Line Items [Line Items]
Sensitivity analysis for types of market risk, reasonably possible change in risk variable, impact on pre-tax earnings	$ 44

Note 5 - Financial Instrument26

Note 5 - Financial Instruments - Classes of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Cash and cash equivalents, consisting of high interest savings accounts, treasury bill and short term bankers’ acceptance, classified as loans and receivables and measured at amortized cost [member]
Statement Line Items [Line Items]
Financial assets	$ 17,944	$ 10,631
Investments, consisting of fixed income securities, classified as loans and receivables and measured at amortized cost [member]
Statement Line Items [Line Items]
Financial assets	520	798
Accounts payable and accrued liabilities, measured at amortized cost [Member]
Statement Line Items [Line Items]
Financial liabilities	$ 2,401	$ 1,765

Note 5 - Financial Instrument27

Note 5 - Financial Instruments - Currency Risk (Details) - Currency risk [member] - CAD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Statement Line Items [Line Items]
Balance, end of period	$ 580	$ 699
Cash and cash equivalents [member]
Statement Line Items [Line Items]
Financial assets	303	83
Invesmtents [member]
Statement Line Items [Line Items]
Financial assets	706	1,000
Accounts payable and accrued liabilities [member]
Statement Line Items [Line Items]
Accounts payable and accrued liabilities	$ (429)	$ (384)

Note 6 - Share Capital (Details

Note 6 - Share Capital (Details Textual) - USD ($)	Jun. 08, 2018	Oct. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Dec. 29, 2017	May 30, 2018	Mar. 28, 2018	Oct. 27, 2017	Apr. 02, 2015
Statement Line Items [Line Items]
Issue of equity					$ 5,246,000	$ 8,204,000
Aspire purchase agreement [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value											$ 15,500,000
Total number of shares issued		357,143
Weighted average share price					2.87
Proceeds from Issuing Shares, Gross		$ 500,000			15,000,000		$ 15,500,000
Proceeds from issuing shares		$ 324,000			$ 15,000,000
Number of Shares Issued During the Period					5,231,953
Aspire purchase agreement [member] | Common shares to Aspire Capital in consideration for entering into the Aspire Purchase Agreement [member]
Statement Line Items [Line Items]
Total number of shares issued											321,429
Aspire purchase agreement 2018 [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value									$ 20,000,000
Total number of shares issued	170,261
Value of shares issued during the period	$ 600,000
At the market equity facility [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value												$ 20,000,000
Total number of shares issued				7,472,618		7,472,618
Proceeds from Issuing Shares, Gross				$ 8,500,000
Proceeds from issuing shares				$ 8,200,000
Equity Issuance, Commission Percentage				3.00%		3.00%
Issue of equity								$ 20,000,000
Shares Issued, Price Per Share				$ 1.14		$ 1.14
Cantor Fitzgerald [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value										$ 30,000,000
Total number of shares issued			1,429,847		1,429,847		1,429,847
Weighted average share price			$ 3.78		$ 3.78
Proceeds from Issuing Shares, Gross			5,410,000		5,410,000
Proceeds from issuing shares			$ 5,250,000		$ 5,250,000
Equity Issuance, Commission Percentage			3.00%		3.00%		3.00%

Note 6 - Share Capital - Loss P

Note 6 - Share Capital - Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Issued common shares, beginning of period (in shares)	32,225	18,944	27,502	15,722
Effect of ATM issuances (in shares)	459	2,362	231	3,651
Effect of shares issued pursuant to share purchase agreements (in shares)	1,257		3,007
Effect of exercise of stock options (in shares)	9		4
Effect of RSUs redemptions (in shares)		3		2
Issued common shares, end of period (in shares)	33,950	21,309	30,744	19,375

Note 7 - Other Equity (Details

Note 7 - Other Equity (Details Textual)	Mar. 28, 2017	Jun. 30, 2018USD ($)shares	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)shares	Jun. 30, 2017USD ($)
Statement Line Items [Line Items]
Number of share options granted in share-based payment arrangement				2,084,000	728,000
Number of shares reserved for issue under options and contracts for sale of shares | shares		6,021,923		6,021,923
First set of stock options issued in a share-based payment arrangement [member]
Statement Line Items [Line Items]
Share-based payment arrangements, option vesting percentage, year one				50.00%
Share-based payment arrangements, option vesting percentage, year two				16.67%
Share-based payment arrangements, option vesting percentage, year three				16.67%
Share-based payment arrangements, option vesting percentage, year four				16.67%
Second set of stock options issued in a share-based payment arrangement [member]
Statement Line Items [Line Items]
Share-based payment arrangements, option vesting percentage, year one				50.00%
Share-based payment arrangements, option vesting percentage, year two				25.00%
Number of share options granted in share-based payment arrangement				116,000
Share-based payment arrangements, option vesting percentage, year three				25.00%
Third set of stock options issued in a share-based payment arrangement, vesting immediately [member]
Statement Line Items [Line Items]
Number of share options granted in share-based payment arrangement				850,000
Stock options [member]
Statement Line Items [Line Items]
Expense from share-based payment transactions with employees		$ 515,000	$ 286,000	$ 2,743	$ 339,000
Restricted share units [member]
Statement Line Items [Line Items]
Expense from share-based payment transactions with employees		$ 0	$ 163,000	$ 0	$ 171,000
Number of other equity instruments granted in share-based payment arrangement	150,000				150,000

Note 7 - Other Equity - Stock O

Note 7 - Other Equity - Stock Option Transactions (Details)	6 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)
Statement Line Items [Line Items]
Outstanding, Beginning of period	2,344,000	2,005,000
Outstanding, Beginning of period, weighted average exercise price	$ 3.46	$ 4.31
Stock options, granted	2,084,000	728,000
Stock options, weighted average exercise price, granted	$ 2.96	$ 1.10
Stock options, exercised	(77,000)
Stock options, weighted average exercise price, exercised	$ 2.31
Stock options, forfeited	(17,000)	(142,000)
Stock options, weighted average exercise price, forfeited	$ 2.01	$ 3.65
Stock options, expired		(263,000)
Stock options, weighted average exercise price, expired		$ 4.97
Outstanding, end of period	4,334,000	2,328,000
Outstanding, end of period, weighted average exercise price	$ 3.16	$ 3.40

Note 7 - Other Equity - Stock32

Note 7 - Other Equity - Stock Options Outstanding (Details)	Jun. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)
Statement Line Items [Line Items]
Options outstanding	4,334,000	2,344,000	2,328,000	2,005,000
Options outstanding, weighted average contractual life	8.2
Options outstanding, weighted average exercise price	$ 3.16	$ 3.46	$ 3.40	$ 4.31
Options exercisable	2,561,000
Options exercisable, weighted average exercise price	$ 3.51
Range one [member]
Statement Line Items [Line Items]
Options outstanding	824,000
Options outstanding, weighted average contractual life	8.5
Options outstanding, weighted average exercise price	$ 1.26
Options exercisable	401,000
Options exercisable, weighted average exercise price	$ 1.28
Range one [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	1.03
Range one [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 2.66
Range two [member]
Statement Line Items [Line Items]
Options outstanding	790,000
Options outstanding, weighted average contractual life	9.6
Options outstanding, weighted average exercise price	$ 2.78
Options exercisable	790,000
Options exercisable, weighted average exercise price	$ 2.78
Range two [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	2.67
Range two [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 2.85
Range three [member]
Statement Line Items [Line Items]
Options outstanding	359,000
Options outstanding, weighted average contractual life	7.9
Options outstanding, weighted average exercise price	$ 2.91
Options exercisable	184,000
Options exercisable, weighted average exercise price	$ 2.91
Range three [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	2.86
Range three [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 3
Range four [member]
Statement Line Items [Line Items]
Options outstanding	1,165,000
Options outstanding, weighted average contractual life	9.5
Options outstanding, weighted average exercise price	$ 3.09
Options exercisable	28,000
Options exercisable, weighted average exercise price	$ 3.70
Range four [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	3.01
Range four [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 3.97
Range five [member]
Statement Line Items [Line Items]
Options outstanding	1,196,000
Options outstanding, weighted average contractual life	6.1
Options outstanding, weighted average exercise price	$ 4.87
Options exercisable	1,158,000
Options exercisable, weighted average exercise price	$ 4.86
Range five [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	3.98
Range five [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 32.88

Note 7 - Other Equity - Stock33

Note 7 - Other Equity - Stock Option Fair Value Assumptions (Details) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Weighted average risk-free interest rate	2.39%	1.24%
Expected dividend yield
Weighted average expected volatility	93.90%	100.20%
Weighted average expected life of options (in years)	5	5
Weighted average grant date fair value	$ 2.14	$ 0.81

Note 7 - Other Equity - Restric

Note 7 - Other Equity - Restricted Share Activity (Details) - Restricted share units [member]	Mar. 28, 2017	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)
Statement Line Items [Line Items]
Outstanding, beginning of period
Outstanding, beginning of period, weighted average grant date fair value
Granted	150,000		150,000
Granted, weighted average grant date fair value			$ 1.14
Redeemed			(150,000)
Redeemed, weighted average grant date fair value			$ 1.14
Outstanding, end of period
Outstanding, end of period, weighted average grant date fair value

Note 8 - Additional Cash Flow35

Note 8 - Additional Cash Flow Disclosures - Net Change in Non-cash Operating Working Capital (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Prepaid expenses and other assets	$ (247)	$ 119	$ (197)	$ 262
Accrued payables and accrued liabilities	196	(750)	636	(309)
Net (used) provided	$ (51)	$ (631)	$ 439	$ (47)

Note 9 - Other Expenses (Detail

Note 9 - Other Expenses (Details Textual) - USD ($) $ in Thousands	Jun. 13, 2018	May 07, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Research and development expense, license fee			$ 5,000		$ 5,000
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member]
Statement Line Items [Line Items]
Research and development expense, license fee		$ 2,000
CrystalGenomics [member] | Exclusive license to cg806 in China [member]
Statement Line Items [Line Items]
Research and development expense, license fee	$ 3,000

Note 9 - Other Expenses - Compo

Note 9 - Other Expenses - Components of Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Program costs, excluding salaries	$ 2,201	$ 692	$ 4,476	$ 1,939
Salaries	457	314	946	743
License fee, CrystalGenomics (note 9(a),(b))	5,000		5,000
Stock-based compensation	152	73	519	123
Depreciation and amortization	8	9	17	18
	$ 7,818	$ 1,088	$ 10,958	$ 2,823

Note 9 - Other Expenses - Com38

Note 9 - Other Expenses - Components of General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
General and administrative excluding salaries	$ 1,003	$ 560	$ 2,296	$ 1,268
Salaries	533	443	1,074	1,301
Stock-based payment financing fees (note 6(a)(iii)	600		600
Stock-based compensation	364	376	2,225	386
Depreciation and amortization	11	14	18	28
General and administrative	$ 2,511	$ 1,393	$ 6,213	$ 2,983

Note 9 - Other Expenses - Com39

Note 9 - Other Expenses - Components of Finance Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Foreign exchange loss	$ 11		$ 28
Interest income	74	11	118	19
Foreign exchange gain		29		54
	$ 74	$ 40	$ 118	$ 73

Note 10 - Commitments, Contin40

Note 10 - Commitments, Contingencies and Guarantees (Details Textual) - USD ($) $ in Millions	Jun. 30, 2018	Jun. 13, 2018
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member] | Development Milestones [Member]
Statement Line Items [Line Items]
Possible future milestone payment	$ 16
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member] | Regulatory Milestones [Member]
Statement Line Items [Line Items]
Possible future milestone payment	44
CrystalGenomics [member] | Exclusive license to cg806 in China [member] | Development Milestones [Member]
Statement Line Items [Line Items]
Possible future milestone payment		$ 6
CrystalGenomics [member] | Exclusive license to cg806 in China [member] | Regulatory Milestones [Member]
Statement Line Items [Line Items]
Possible future milestone payment		$ 20
Clinical development of APTO-253 and CG'806 [member]
Statement Line Items [Line Items]
Transaction price allocated to remaining performance obligations	$ 3.2

Note 10 - Commitments, Contin41

Note 10 - Commitments, Contingencies and Guarantees - Operating Lease Commitments (Details) $ in Thousands	Jun. 30, 2018USD ($)
Statement Line Items [Line Items]
Operating leases	$ 1,516
Not later than one year [member]
Statement Line Items [Line Items]
Operating leases	280
Later than one year and not later than three years [member]
Statement Line Items [Line Items]
Operating leases	505
Later than three years and not later than five years [member]
Statement Line Items [Line Items]
Operating leases	518
Later than five years [member]
Statement Line Items [Line Items]
Operating leases	$ 213

Note 11 - Related Party Trans42

Note 11 - Related Party Transactions (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	May 31, 2017
Statement Line Items [Line Items]
Services to be received, related party transactions, maximum			$ 300,000
Services received, related party transactions	$ 143,000	$ 122,000